451 related articles for article (PubMed ID: 26030409)
21. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
[TBL] [Abstract][Full Text] [Related]
22. Cardiolipin remodeling by TAZ/tafazzin is selectively required for the initiation of mitophagy.
Hsu P; Liu X; Zhang J; Wang HG; Ye JM; Shi Y
Autophagy; 2015 Apr; 11(4):643-52. PubMed ID: 25919711
[TBL] [Abstract][Full Text] [Related]
23. Cardiac and skeletal muscle defects in a mouse model of human Barth syndrome.
Acehan D; Vaz F; Houtkooper RH; James J; Moore V; Tokunaga C; Kulik W; Wansapura J; Toth MJ; Strauss A; Khuchua Z
J Biol Chem; 2011 Jan; 286(2):899-908. PubMed ID: 21068380
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of mitochondrial oxodicarboxylate carrier (ODC1) preserves oxidative phosphorylation in a yeast model of Barth syndrome.
de Taffin de Tilques M; Tribouillard-Tanvier D; Tétaud E; Testet E; di Rago JP; Lasserre JP
Dis Model Mech; 2017 Apr; 10(4):439-450. PubMed ID: 28188263
[TBL] [Abstract][Full Text] [Related]
25. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
26. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
27. Defective Mitochondrial Cardiolipin Remodeling Dampens HIF-1α Expression in Hypoxia.
Chowdhury A; Aich A; Jain G; Wozny K; Lüchtenborg C; Hartmann M; Bernhard O; Balleiniger M; Alfar EA; Zieseniss A; Toischer K; Guan K; Rizzoli SO; Brügger B; Fischer A; Katschinski DM; Rehling P; Dudek J
Cell Rep; 2018 Oct; 25(3):561-570.e6. PubMed ID: 30332638
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial dysfunctions in barth syndrome.
Ghosh S; Iadarola DM; Ball WB; Gohil VM
IUBMB Life; 2019 Jul; 71(7):791-801. PubMed ID: 30746873
[TBL] [Abstract][Full Text] [Related]
29. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
30. Plasmalogen loss caused by remodeling deficiency in mitochondria.
Kimura T; Kimura AK; Ren M; Monteiro V; Xu Y; Berno B; Schlame M; Epand RM
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31434794
[TBL] [Abstract][Full Text] [Related]
31. Acquired deficiency of tafazzin in the adult heart: Impact on mitochondrial function and response to cardiac injury.
Szczepanek K; Allegood J; Aluri H; Hu Y; Chen Q; Lesnefsky EJ
Biochim Biophys Acta; 2016 Apr; 1861(4):294-300. PubMed ID: 26692032
[TBL] [Abstract][Full Text] [Related]
32. Mechano-energetic aspects of Barth syndrome.
Dudek J; Maack C
J Inherit Metab Dis; 2022 Jan; 45(1):82-98. PubMed ID: 34423473
[TBL] [Abstract][Full Text] [Related]
33. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
34. Barth syndrome in a female patient.
Cosson L; Toutain A; Simard G; Kulik W; Matyas G; Guichet A; Blasco H; Maakaroun-Vermesse Z; Vaillant MC; Le Caignec C; Chantepie A; Labarthe F
Mol Genet Metab; 2012 May; 106(1):115-20. PubMed ID: 22410210
[TBL] [Abstract][Full Text] [Related]
35. Cardiolipin remodeling: a regulatory hub for modulating cardiolipin metabolism and function.
Ye C; Shen Z; Greenberg ML
J Bioenerg Biomembr; 2016 Apr; 48(2):113-23. PubMed ID: 25432572
[TBL] [Abstract][Full Text] [Related]
36. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
37. Decreased pyruvate dehydrogenase activity in Tafazzin-deficient cells is caused by dysregulation of pyruvate dehydrogenase phosphatase 1 (PDP1).
Liang Z; Ralph-Epps T; Schmidtke MW; Kumar V; Greenberg ML
J Biol Chem; 2024 Mar; 300(3):105697. PubMed ID: 38301889
[TBL] [Abstract][Full Text] [Related]
38. Cardiolipin function in the yeast S. cerevisiae and the lessons learned for Barth syndrome.
Ji J; Greenberg ML
J Inherit Metab Dis; 2022 Jan; 45(1):60-71. PubMed ID: 34626131
[TBL] [Abstract][Full Text] [Related]
39. New C-Terminal Conserved Regions of Tafazzin, a Catalyst of Cardiolipin Remodeling.
Shilovsky GA; Zverkov OA; Seliverstov AV; Ashapkin VV; Putyatina TS; Rubanov LI; Lyubetsky VA
Oxid Med Cell Longev; 2019; 2019():2901057. PubMed ID: 31781330
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
